semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 55.0-75.0,  Healthy Volunteers Provide a signed written informed consent Age 55-75 inclusive ECG within normal limits Body mass index (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2 Negative urine drug screen for selected drugs of abuse at screening Negative for hepatitis and HIV at screening Good general health, as determined by medical history, physical examination, and clinical laboratory testing Willingness to stay in the unit overnight for the duration of the study Consent for CSF collection (for those in CSF group)  Current smokers, or ex-smokers with a remote history (> 100 pack/year) Clinically significant medical conditions History of ECG abnormalities Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in absence of febrile episodes, in the last 14 days History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism, and excretion of drugs Malignancy, regardless of location Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis Investigational agents are prohibited one month prior to entry and for the duration of the trial Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 19.0-80.0,  Stenosis Fusion of Spine (Disease) Patients who need lumbar interbody fusion in Degenerative spine disease on L1-S1(Spinal stenosis, HIVD and internal derangement of disk, spine instability) Patients who have no communication problems Patients who are willing to visit the hospital for any follow-up assessment Patients who voluntarily sign on a written consent  Patients who have infection Patients who have bleeding disorders Patients who have immunosuppressed disease Patients who can't sign on consent form Patients who are in pregnancy or breast feeding Patients who have severe osteoporosis Patients who can't take general surgery because of severe liver disease or decreased renal function Patients who have acute spinal injury, spinal tumor or inflammatory spinal disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Statin Intolerance Patient Must be between 30-75 years of age LDL>100mg/dL VO2 max greater than 25 ml/kg/min Patient  Liver or kidney disease Currently taking drugs that interfere with statin metabolism Currently taking blood thinners Acute or chronic infectious disease; autoimmune/inflammatory disease, cancer, COPD, anemia, psychiatric illness, insulin-dependent diabetes smokers or illicit drug users adverse cardiovascular event (ex: heart attack) history of knee surgery or active history of knee pain
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 8.0-70.0,  Friedreich's Ataxia Genetic diagnosis of Friedreich's ataxia by DNA sequencing, mutational analysis or protein assay OR be a healthy subject with no evidence of a neuromuscular disorder Between the ages of 8 and 70 (inclusive) Are able to tolerate metabolic exercise testing Are stable on cardiac medication regimen for 3 months prior to screening  Presence of unstable heart disease Receipt of cardiac transplant Any concurrent medical condition which, in the opinion of the investigators, would make the subject unsuitable for the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Glucose-6-Phosphate Dehydrogenase Deficiency All children with proved enzymatic deficiency of G6PD Patients who met the of hemoglobin level at study time ≥ 11 gm/dl  patients with another enzyme deficiency
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Tobacco Smoking Pregnancy the woman presents for her first prenatal visit before 14-week gestation she is a smoker years or older (legal age for consent and for consuming tobacco in Romania) married or in a stable relationship phone service in the home or mobile phone willing to have the partner contacted for participation, upon brief explanation of the study  partner declines participation upon phone recruitment attempt
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-89.0,  Musculoskeletal Pain Pain All hemodynamically stable, adult patients presenting to the Emergency Department (ED) with a chief complaint of pain AND a physician diagnosis of acute, non-critical, musculoskeletal pain Musculoskeletal pain includes pain to any bones, muscles, cartilage, or nerves associated with such Patients will be diagnosed by a physician as non-critical meaning they can be treated and sent home without needing to be admitted to the hospital Blood pressure: 90-180/60-110 Cardiac rate with no dysrhythmias 50-149 Ventilatory rate 10-35 Oxygen saturation >87% Alert and able to follow commands and respond appropriately  Patients that are altered and/or present with vital signs outside of the ranges Those deemed in critical condition by triage nurse and/or ER physician Patients with a history of narcotic drug abuse/dependency Patients who have had Battlefield Acupuncture done in the past Pregnant or nursing women (confirmed by a pregnancy test) Allergic to adhesive tape, gold, or other needle components Allergic to aspirin, NSAIDs, or narcotics Patients at risk for complications from indwelling acupuncture needles, such as patients with bleeding disorders, those who are immunosuppressed, or those with liver disease (Hepatitis C, cirrhosis, etc.)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-25.0,  Back Injuries Basketball players, between 18-25 years who participate on a official league and do regular physical training (4 training sessions 1.5 hours each and a competitive session a week) Be able to read and understand the premises of the informed consent of the study  to present some osteo-articular and / or muscle-tendon pathology that could be exacerbated by the implementation of the Biering-Sorensen test or by the intervention with foam compression
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pregnancy Pregnant women at ≥37 weeks gestation by reliable dating as determined by the American College of Obstetricians and Gynecologists (i.e. gestational age supported by one of the following: ultrasound prior to 20 weeks of gestation, fetal heart tones auscultated by Doppler for 30+ weeks, or documented serum or urine pregnancy test 36+ weeks ago) 2. Scheduled induction of labor with indication and timing supported by the Family Birth Center induction of labor guideline entitled "Induction of labor: Indications and Timing" 3. Singleton gestation 4. Cephalic presentation 5. Amniotic fluid index greater than or equal to 5 centimeters 6. Formal prenatal ultrasound documenting the absence of placenta previa 7. Bishop score <6 and cervical dilation <3cm 8. The woman is able to give appropriate consent and has undergone an informed consent process. 9. Maternal age ≥ 18 years old at the time of consent  New diagnosis requiring immediate hospitalization for monitoring (such as new onset hypertensive disease of pregnancy) 2. Vaginal bleeding 3. Active labor 4. Premature rupture of membranes as determined by positive ferning and as supported by pooling of fluid in the vaginal vault. 5. Uterine tachysystole (>5 contractions in 10 minutes) 6. Nonreassuring fetal heart tracing before or after Foley placement 7. Chorioamnionitis or maternal fever 8. Intrauterine fetal demise 9. Contraindication to vaginal delivery, relative or absolute (i.e. transfundal uterine surgery) 10. Abnormal placentation including a low lying placenta 11. Prior cesarean delivery 12. Intrauterine growth restriction (growth <10th percentile by formal ultrasound) 13. Known fetal anomaly 14. Human immunodeficiency virus, Hepatitis C, or active herpes infection 15. Maternal cardiopulmonary disease requiring cardiac monitoring during labor 16. Pregestational diabetes 17. Rh isoimmunization 18. Non-English speaking 19. Distance from the hospital over 60 minutes by car, unreliable communication via telephone, or unreliable transportation
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  Cardiovascular Disease Risk Factors Men and women 30-65 years of age 2. BMI ≥ 18 and ≤ 39 kg/m^2 3. Total cholesterol below 273 mg/dL for men and below 284 mg/dL for women 4. Triglycerides below 350 mg/dL 5. Non-smokers 6. At least one of the following: 1. Systolic blood pressure 120-159 mmHg 2. Diastolic blood pressure 80-99 mmHg  History of acute or chronic inflammatory conditions or heart disease, kidney disease, liver disease, autoimmune disorders, or thyroid disease (unless controlled by medication and blood results within previous 6 months are provided) 2. History of diabetes mellitus (and/or a fasting glucose >126 mg/dL at screening) 3. Stage II hypertension (blood pressure ≥ 160/100 mmHg) 4. Lactation, pregnancy, or desire to become pregnant during the study 5. Unwillingness to discontinue nutritional supplements, herbs, or vitamins unless approved by investigator 6. Use of medications/supplements for elevated lipids, blood pressure, or glucose 7. Chronic use of non-steroidal anti-inflammatory or immunosuppressant medication 8. Conditions requiring the use of steroids 9. Unwillingness to refrain from blood donation prior to and during the study 10. Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator 11. Allergy or sensitivity to cranberry juice or any ingredient in the study beverages
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 25.0-80.0,  Head and Neck Cancer Able to read and write in the English language Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014 Able to travel to the MSK outpatient clinic or have access to email, the MSK patient portal and a computer with a camera for the follow up examination by a physician and completion of the questionnaires  Patients who underwent marginal mandibulectomy Patients who underwent mandibular reconstruction with a different type of vascularized bone free flap Patients who underwent mandibular reconstruction with soft tissue free flap
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Episodic or Chronic Cluster Headache People aged 18 or over Patient consulting in Marseille's or Nice's Pain departments Patient agreeing to participate to the research study Patient with health insurance  People aged under 18 Patient refusing to participate to the research study Patient with deprivation of liberty
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Patient ≥ 18 years old Male or Female Type 2 diabetes patients Uncontrolled with previous therapy (HbA1c >7%), evident in HbA1c test within the last 1 month before study entry Insulin naïve patients: any patient uncontrolled after one or a maximum of two lines of therapy including: monotherapy (Metformin alone or any other Oral Anti-Diabetic agent (OAD) if contraindicated or intolerance) and/or dual therapy (any OAD combination), at maximum tolerated dose in the last 3 months Signed informed consent Signed informed consent  Patient not willing or not able to perform self-monitoring blood glucose Patient not willing or not able to self-titrate insulin glargine under physician's guidance Patient not suitable for participation according to what is specified in the approved Summary of Product's Characteristics or according to medical or clinical conditions, as judged by the Investigator History of impaired hepatic function defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than three times the upper limit of normal, evident in testing done in the last 3 months History of impaired renal function defined as serum creatinine >135 μmol/L (>1.525 mg/dL)in men and >110 μmol/L (>1.243 mg/dL) in women, evident in testing done in the last 3 months Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method at physician's discretion) Treatment with systemic corticosteroid within 3 months prior to study entry. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Head and Neck Neoplasms The study will patients planned for free anterolateral thigh/fibula or scapula flap for Head&Neck cancer reconstruction The patients should have a complete and detailed medical record Subjects must be at least 18 years of age Subjects must sign and be given a copy of the written Informed Consent Form  Patients who are not able to consent by themselves or grasp the implication of the study Subjects participating in any other clinical trial during the time of this clinical investigation and that may have an impact on this evaluation Pregnant or potentially pregnant woman Lactation Iodine, shellfish, cough mixture, betadine or ICG allergy The for the IV contrast detailed in appendix 2
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Submucous Fibrosis Consenting adults 2. Both gender 3. Age: 20-65 years 4. Normal preoperative upper airway evaluation and without the presence of anticipated airway access difficulty 5. Patients scheduled for surgery under general anaesthesia with airway control by direct laryngoscopy and tracheal intubation  Patient refusal 2. Anticipated airway access difficulty 3. Edentulous patients 4. Patients with dental problem (missing tooth, overlap, cosmetic treatment) 5. Vulnerable Patients: High risk situation, major surgery, extremes of age, obstetric patients 6. Previously difficult airway
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency biochemical evidence of vitamin D deficiency  renal disease or stones or hypercalcaemia, 2. Use of calcium and/or vitamin D supplementation, bisphosphonates, steroid medications, hormones or diuretics
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Sclerosis Calcinosis Signed written informed consent Age > 18 years of age Diagnosis of limited or diffuse cutaneous systemic sclerosis (SSc) according to the revised 2013 ACR/EULAR classification for SSc Radiological and physical examination evidence of at least one subcutaneous calcium deposition in the hands that is clinically apparent as part of routine clinical care If female of childbearing potential, the patient must have a negative pregnancy test at screening and baseline visits Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to screening and throughout the study Calcium channel blockers, alpha-1-antagonists, ACE-inhibitors, angiotensin receptor blockers, and protein-pump inhibitors are permitted as long as the doses are stable for 4 weeks prior to screening and throughout the study Women of childbearing potential must agree to use adequate contraception when sexually active with any combination of at least 2 effective methods of birth control (except for women who have a partner who is sterile, i.e. due to vasectomy)  Rheumatic disease other than SSc Patients with pulmonary arterial hypertension (PAH), NYHA Class III or IV, as determined by right heart catheterization or on PAH approved medications for PAH Patients with moderate or severe hepatic impairment (Child Pugh Class C), or transaminase elevation (ALT or AST) > 3 x the upper limit of normal at screening visit Patients with diverticulosis Hemoglobin < 75% of the lower limit of the normal range Systolic blood pressure < 95 mmHg or diastolic blood pressure < 50 mmHg Patients who are hemodynamically unstable, or have acute renal, cardiac or pulmonary failure, or any life-threatening condition Concurrent malignancy except non-melanoma skin cancers Patients receiving specific (sildenafil, tadalafil) or unspecific phosphodiesterase-5 inhibitors (dipyridamole, theophylline), endothelin receptor antagonists, prostanoids, riociguat, or NO donors (nitrates) within 4 weeks of screening Patients receiving bisphosphonates, warfarin, colchicine, minocycline, intravenous immunoglobulins, or biological agents including abatacept or rituximab within 4 weeks of screening